NICTUR Trademark
NICTUR is a USPTO trademark filed by GP PHARM, S.A.. Status: Cancelled.
Trademark Facts
| Mark | NICTUR |
|---|---|
| Serial Number | 79228430 |
| Registration Number | 5663531 |
| Status | Cancelled |
| Filing Date | 2017-11-10 |
| Registration Date | 2019-01-29 |
| Mark Type | Word |
| Nice Classes | 005 (Pharmaceuticals) |
| Owner | GP PHARM, S.A. |
| Attorney of Record | Elizabeth Lee |
| Prosecution Events | 30 |
| Latest Event | INTR on 2026-04-15 |
Goods & Services
Pharmaceutical preparations for human use for treating nighttime or daytime enuresis, primary nocturnal enuresis, nocturia, Von Willebrand-Jurgens disease, hemorrhaging, bleeding in patients with Hemophilia A, postoperative bleeding and diabetes insipidus, for the management of surgical hemostasis, for use in renal concentrating capacity test, for use in oncology, for treating cancer, for treating cardiovascular diseases, for use as antivirals, for treating inflammatory diseases and disorders of the intestine, for treating inflammatory diseases and disorders of the connective tissue, for treating arthritis, for treating urological diseases and disorders, for treating hormonal diseases and disorders, for treating endocrinological diseases and disorders, for treating psychiatric diseases and disorders, in particular mood disorders, anxiety disorders, cognitive disorders and schizophrenia, for treating neurological and neurodegenerative diseases and disorders, in particular, dementia linked to Alzheimer's disease, Huntington's disease, Parkinson's disease, cerebral palsy, brain injuries and diseases, injuries and diseases of the spinal cord, convulsive disorders, epilepsy, encephalitis, disorders of the central nervous system, ocular motility disorders, dystonia, blepharospasm, strabismus, facial scoliosis and tics, cerebral ischemia, dementia, amyotrophic sclerosis, and lateral multiple sclerosis, for treating auto-immune diseases and disorders, for treating transplant rejection, for treating ophthalmological diseases and disorders such as proliferative or non-proliferative diabetic retinopathy, macular degeneration, age-related macular degeneration, retinal neovascularization, neovascularization associated with choroidal melanoma, retinopathy, central retinal vein occlusion, pigmentary retinitis, uveitis, macular edema and cystoid macular edema; synthetic peptides for the treatment of urological, endocrine and blood diseases and disorders